WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Transplant Product Efficacy Framework v8-2, Banff grade is staged as IIB, defined time points including 12 months, Estimated GFR (eGFR) accounts for Serum Creatinine (SCr), Banff grade is staged as IIA, Transplant Donor has Medical History, Approved Concomitant Anti-rejection therapy has (1..n) Drug Name, EBV increases risk for PTLD (post-transplant lymphoproliferative disorder), Study Drug has value for Dosage, Study Drug taken in combination with Induction Agent, Glomerular Filtration Rate (GFR) is associated with Cardiovascular (CV) risk, CV death can result from Toxicity, Estimated GFR (eGFR) is correlated with Graft Loss, Transplant Donor has HLA types, Transplant Donor can be Living-non-related, Chronic Allograft Insufficiency (CAI) reported as yes, defined time points including 12 months, Actual Trough Concentration measured for Study Drug, Banff grade accounts for C4d status, Banff grade accounts for Tubulitis, Transplant Donor provides Organ